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letters
spending on HiV
HIV funding: debate misses  
the point
As one who has lost five out of 11 siblings 
to HIV, I cannot but be aware of the 
magnitude of HIV. Though the figures 
of England and de Lay et al differ,1 2 the 
element of relative overspending on HIV 
compared with other health and social 
developmental sectors is obvious.
Both miss the crucial point that HIV 
is the only tropical disease receiving 
anywhere near Western rates of health 
funding. The reasons for this include 
the global nature of HIV, the wages and 
expenses of expatriate health workers, 
and the many groups working with HIV 
in the tropics. England could have argued 
that the money channelled into HIV 
should be spent through local national 
health departments. Some African non-
governmental organisations and de Lay et 
al may argue for the status quo, which has 
created, in some cases to the detriment of 
health and governance institutions, parallel  
institutions as it benefits their causes. 
England should have presented a 
breakdown of how the HIV funding is 
being used. He may find that only a small 
fraction trickles down to African patients 
with HIV and that a significant chunk 
bounces back to the West.3
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It’s only numbers
Both England and de Lay et al play the 
numbers game of statistics, economy, and 
modelling of the future.1 2 But I guess that 
none of the authors is HIV positive or a 
doctor and so can sit safely behind a desk 
jettisoning numbers to the audience.
HIV, tuberculosis, and malaria are 
among the greatest killers of the poorest 
people in the world, claiming about 1 
million lives each per annum, or 114 
people every hour of every day, disabling 
the future economies and existence of 
the poorest nations. Yet, has the world 
conquered even one of the big three? If a 
glimmer of hope to save the future deaths 
came from heavy investment in immune 
damage from any of the big three, then 
every penny spent is worth while. To 
change public attitudes will take decades, 
unlike the immediate and positive effect of 
Princess Diana holding the hand of a patient 
with AIDS before the media. Until then 
money must be invested in trying to stem 
the tide of death for today and tomorrow.
“Fiddling while Africa burns” is a common 
issue, when words from desk jockeys take 
centre stage and engage debate and not 
action. No author brings a primary solution 
to the table, but rather each mildly lambasts 
world authorities and nation leaders for fiscal 
mishandling. A weak debate. In the time it 
has taken you to read this another person has 
died of AIDS—a fact of life.
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pandemic flu
Look at all the evidence before 
stockpiling amantadine
Tsiodras et al propose testing amantadine 
to see if any benefits could accrue in 
combination with neuraminidase inhibitors 
in pandemic flu.1 The principal attraction 
seems to be low cost. Although they quote 
resistance and harms as well as lack of “any 
demonstrable reduction in transmissibility 
or pathogenicity,” this does not seem to 
deter them from their proposal.
Had they consulted the Cochrane Library, 
they would have discovered that amantadine 
(the only adamantane for which we have 
a reasonable knowledge base) relieves or 
suppresses symptoms if taken within 48 
h, but it does not prevent infection with 
influenza A viruses or stop their nasal 
excretion. This is the key finding in a 
pandemic as apparently healthy individuals 
devoid of symptoms and feeling good 
because they have taken “the pill” would be 
spreading influenza viruses in the community 
through contact and droplets. Amantadine 
suppresses symptoms but not infection, 
it does not prevent or even diminish the 
risk of influenza communication, it causes 
unacceptable harms, resistance to it is 
widespread and swiftly induced: it is a very 
dangerous drug, especially in a pandemic.2
Would the authors give prophylactic 
amantadine to essential workers knowing 
it causes gastrointestinal symptoms (mainly 
nausea, odds ratio 2.56; 95% confidence 
interval 1.37 to 4.79) and insomnia and 
hallucinations (2.54; 1.50 to 4.31) and 
caused withdrawals from the trials because 
of adverse events (2.54; 1.60 to 4.06)?2 
Would they give it to ambulance drivers, 
train conductors, and helicopter pilots?
If pharmacological intervention is 
required to help contain a pandemic, then 
neuraminidase inhibitors are far safer and 
more effective than adamantanes.3 No 
benefit, but a lot of harm will accrue with 
continued use of amantadine. That is what 
all available comparative evidence shows.
Tom Jefferson, Cochrane Acute Respiratory Infections 
Group, Anguillara Sabazia, Rome 00061, Italy  
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WHo funding
World Health organization 
refutes allegations
The World Health Organization 
categorically rejects the allegations made 
in a recent story in the BMJ which imply 
that WHO solicits money from the 
pharmaceutical sector through independent 
organisations by circumventing its own 
rules.1
As the BMJ correctly reports, WHO has 
clear guidelines against seeking or accepting 
funds from commercial enterprises or 
through third parties where there would be 
a conflict of interest.
When WHO does accept donations or 
funds from pharmaceutical companies—
for example, donations of vaccines or 
medicines—those donations are clearly 
accounted for and transparently reported.
In this specific case, Dr Benedetto 
Saraceno was very clear. He had never 
asked that funds be solicited from the 
pharmaceutical sector, and he declined the 
funds that were offered.
WHO is concerned about the BMJ ’s 
depiction of Dr Saraceno. He is a 
professional of deep personal integrity. In 
the 10 years he has been with WHO, Dr 
Saraceno has tirelessly worked to highlight 
the public health consequences and grave 
inequalities faced by the millions of people 
who are affected by mental, neurological, or 
behavioural disorders.
Christine McNab, acting director of communications, World 
Health organization, 20 Avenue Appia, 1211 Geneva 27, 
Switzerland mcnabc@who.int
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randomised trials
The urge to sprinkle statistics 
is irresistible
We might be forgiven for believing that 
Glasziou et al had discovered some hitherto 
unknown method of causal inference.1 
Instead they have merely stumbled 
across the way in which causes have been 
identified in everyday life and science 
throughout history.2
The “mother’s kiss” technique for 
removing a bead lodged in a nostril is an 
effective treatment not only because it has 
been shown to work in case reports but 
also because it is grounded in elementary 
principles of physics familiar to every 
child who has played with a pea shooter. It 
does not need statistical analysis. Yet, the 
authors—unable to free themselves of the 
urge to season the data with a sprinkle of 
relative risks or P values—neglect the fact 
that the many examples they provide of 
treatments with clearly observable effects 
are widely accepted without the need for 
statistical tricks.
The obsession with both randomised 
controlled trials and the statistical approach 
to causation has clouded the thinking of a 
generation or more of medical researchers. 
So much so, that the commonsense notion 
of causation has been relegated to little 
more than an afterthought. And this 
accounts for the dismissive approach to any 
data not derived from randomised trials. 
Perhaps, after their damascene conversion, 
Glasziou et al will campaign for a change in 
the hierarchy of evidence in favour of data 
from non-randomised sources.
James Penston, consultant physician, Scunthorpe General 
Hospital, Scunthorpe, North Lincolnshire DN15 7bH  
james.penston@nlg.nhs.uk
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Beware “Texas sharp shooter” 
in rate ratios of progression
Glasziou et al’s method of calculating rate 
ratios of progression (stable unchanging 
condition before v change shortly after the 
intervention) is appealing,1 but we need 
to be wary of a “Texas sharp shooter” 
effect. This effect is usually associated 
in epidemiology with the problem of 
interpreting apparent clusters of disease 
in space, where the geographical unit of 
analysis may have been chosen post hoc 
so as to maximise the apparent density of 
cases as in the joke about a Texan firing 
bullets into the wall of a barn and then 
drawing the targets around the bullet holes 
to show his shooting prowess.
An analogous problem may occur 
when calculating rate ratios in the manner 
described in this article, although the 
sharp shooting is in time, not space. In 
the mother’s kiss, the time period used is 
10s, which gives a rate ratio of progression 
of 1440. Perhaps, however, the bead 
dislodged after only 8 s, a rate ratio of 
1440/0.8=1800. Alternatively, if the bead 
had taken 15 s to dislodge, the doctor, 
nurse, and mother might still reasonably 
have felt that they should take the  
credit for the happy outcome. You need 
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to make an a priori decision about the post 
intervention time frame you will use—
presumably based on the maximum length 
of time after the event you are prepared 
to attribute any improvement to your 
intervention.
anna C Goodman, PhD student, London School of Hygiene 
and Tropical Medicine, London WC1e 7HT  
anna.goodman@lshtm.ac.uk
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morpHine
Double effect is a myth leading 
a double life
Kelly Taylor’s request to use morphine “to 
make her unconscious” under the principle 
of double effect is a puzzling choice.1
Evidence over the past 20 years has 
repeatedly shown that, used correctly, 
morphine is well tolerated and does not 
shorten life or hasten death.2 Its sedative 
effects wear off quickly, toxic doses can 
cause distressing agitation, and it has  
a wide therapeutic range. The Dutch know 
this and hardly ever use morphine for 
euthanasia.3
Palliative care specialists are not faced 
with the dilemma of controlling severe 
pain at the risk of killing the patient: they 
manage pain with drugs and doses adjusted 
to each patient, while at the same time 
helping fear, depression, and spiritual 
distress. Doctors who act precipitously with 
high, often intravenous, doses of opioids 
may do so out of compassionate panic, but 
they are being misled into bad practice 
by the continuing promotion of double 
effect as a real and essential phenomenon 
in end of life care. Using double effect as a 
justification for patient assisted suicide and 
euthanasia on the grounds that it is already 
being done under the rubric of double effect 
is not tenable in evidence based medicine.4
In end of life care double effect is a myth 
leading a double life.
Claud regnard, consultant in palliative care medicine, 
St oswald’s Hospice, Newcastle upon Tyne Ne3 1ee 
claudregnard@stoswaldsuk.org
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